RenovoRx, Inc. 8-K

What Happened RenovoRx, Inc. (RNXT) filed a Form 8-K on March 30, 2026 (Items 2.02 and 8.01) announcing its financial results for the fiscal year ended December 31, 2025 and providing updates to its clinical trial and commercialization strategy. The company’s press release with the full details is attached as Exhibit 99.1 to the filing.

Key Details

• The Form 8-K was filed on March 30, 2026 and covers results as of and for the fiscal year ended December 31, 2025.
• The company issued a press release (Exhibit 99.1) that contains the full financial results and the described clinical/commercial updates.
• Item 2.02 reports results of operations and financial condition; Item 8.01 provides other events (clinical trial and commercialization strategy updates).

Why It Matters For investors, the filing signals material corporate communications: FY2025 financial performance and changes or progress in RenovoRx’s clinical and go-to-market plans can affect valuation and near-term outlook. The press release attached to the 8-K contains the specific financial figures and program details — investors should review Exhibit 99.1 and the company’s full SEC filings to see revenue, net loss/profit, cash position, and any milestone or strategy shifts that could influence the stock or development timeline.